Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Evidence for Positive Selection in the C-terminal Domain of the Cholesterol Metabolism Gene PCSK9 Based on Phylogenetic Analysis in 14 Primate Species

  • Keyue Ding,

    Affiliation Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota, United States of America

  • Samantha J. McDonough,

    Affiliation Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota, United States of America

  • Iftikhar J. Kullo

    To whom correspondence should be addressed. E-mail: kullo.iftikhar@mayo.edu

    Affiliation Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota, United States of America

Evidence for Positive Selection in the C-terminal Domain of the Cholesterol Metabolism Gene PCSK9 Based on Phylogenetic Analysis in 14 Primate Species

  • Keyue Ding, 
  • Samantha J. McDonough, 
  • Iftikhar J. Kullo
PLOS
x

Abstract

Background

Cholesterol homeostasis is maintained through finely tuned mechanisms regulating intestinal absorption, hepatic biosynthesis and secretion as well as plasma clearance. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted enzyme of the serine protease family that reduces cellular uptake of plasma low-density lipoprotein (LDL) cholesterol by promoting LDL receptor (LDL-R) degradation. Species-specific positive selection has been noted in the LDLR promoter, leading to differential expression of LDLR among primates. Whether PCSK9 experienced significant selective pressure to maintain a functional relationship with its target protein, LDL-R, is unknown.

Methodology/Principal Findings

We compiled the sequences of the coding regions of PCSK9 from 14 primate species in the clade of Hominoids, Old World monkeys and New World monkeys. To detect selective pressure at the protein level, the ratios of nonsynonymous/synonymous substitution rate (dN/dS) under different evolutionary models were calculated across the phylogeny of PCSK9. Maximum likelihood analyses of dN/dS ratios for the aligned coding region sequences among 14 primate species indicated that PCSK9 was subject to a strong functional constraint (i.e., purifying selection). However, positive selection was noted in the functional carboxyl-terminal (C-terminal) domain in many branches across the phylogeny, especially in the lineage leading to the orangutan. Furthermore, at least five positively selected amino acids were detected in this lineage using the branch-site model A. In a sliding-window analysis, several dN/dS peaks in the C-terminal domain in both the human and the orangutan branches were noted.

Conclusions

These results suggest that among primates, differential selective pressure has shaped evolutionary patterns in the functional domains of PCSK9, an important regulator of cholesterol homeostasis.

Introduction

The low-density lipoprotein (LDL) receptor gene (LDLR) plays a key role in cholesterol homeostasis by receptor-mediated endocytosis of LDL cholesterol. Proprotein convertase subtilisin/kexin type 9 (PCSK9, MIM 607786) – a secreted enzyme of the serine protease family – is a newly discovered regulator of LDLR [1][3]. The human PCSK9 locus spanning 25 kb and containing 12 exons, resides on chromosome 1p32. The PCSK9 protein contains five functional domains, a signal-peptide and prodomain at its N-terminus, followed by a catalytic domain, a putative domain and a cysteine-rich carboxy-terminal domain [4][6] (Figure 1). PCSK9 induces LDL-R breakdown [7], internalization and recycling [8], [9] and thereby reduces LDL clearance, and increases plasma levels of LDL cholesterol. Overexpression of wild-type Pcsk9 gene in mice results in reduced number of LDL-R and hypercholesterolemia [4], [8], [9].

thumbnail
Figure 1. Distribution of non-synonymous variations along PCSK9.

There are five functional domains in the PCSK9 protein [4][6]: 1) a signal peptide (SP) (1∼30 aa), 2) a prodomain (31∼147 aa), 3) a catalytic domain (148∼425 aa), 4) a putative P domain (426∼525 aa), and 5) a C-terminal domain (526∼691 aa). Gain-of-function mutations are only identified in families with hypercholesterolemia [10] or subjects with high LDL cholesterol levels [17], and loss-of-function mutations in subjects with low levels of LDL cholesterol [15][19]. Some non-synonymous mutations have been identified in subjects with either high or low plasma LDL cholesterol [4], [17], and are labeled ‘both’ in the figure. Rare mutations found in families with autosomal dominant hypercholesterolemia are labeled with an asterisk. The gain-of-function mutations are: S127R, F216L, R237W, D374Y, H417Q, R469W, E482G, F515L and H553R. The loss-of-function mutations are: 14insL, E57K, Y142X, L253F, H391N, Q554E, and C679X. Mutations associated with either high- or low- plasma levels of LDL cholesterol subjects are: R46L, A53V, N425S, A443T, I474V, Q619P, and E670G.

http://dx.doi.org/10.1371/journal.pone.0001098.g001

Mutations in PCSK9 can cause severe autosomal dominant hypercholesterolemia [4], [8][14] (i.e., ‘gain-of-function’ mutations), and also low circulating levels of LDL cholesterol [15][19] (i.e., ‘loss-of-function’ mutations). Kotowski et al. [17] described a spectrum of nonsense/missense mutations in PCSK9 that were associated with low or elevated LDL cholesterol levels, in both black and white subjects. Relatively common sequence variants in PCSK9 also contribute significantly to inter-individual variation in plasma levels of LDL cholesterol in the general population [17]. Cohen et al. [20] showed that two nonsense mutations (Y142X and C679X) in blacks, and one missense mutation (R46L) in whites, were associated with reduced plasma levels of LDL cholesterol and lower incidence of coronary heart disease events. We have summarized these non-synonymous variations in PCSK9 in Figure 1.

Extant primates show a wide range of phenotypic adaptations to diverse environmental conditions, including substrate and diet [21]. Significant differences in lipid profiles occur among primates; for example, New World and Old World monkeys have significantly lower serum total cholesterol, triglycerides, and LDL cholesterol levels than Hominoids [22]. Among Hominoids, gorillas have the highest circulating total cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol levels [22]. Caceres et al. [23] found that several genes related to lipid metabolism were differentially expressed in humans and non-human primates. LDLR has also been shown to be differentially expressed among mammals [24].

Activation of the sterol regulatory element binding protein-2 (SREBP-2), a key transcription factor of LDLR, not only leads to increased expression of LDLR, but also of PCSK9 [25], and the mRNA expression of LDLR and PCSK9 are coordinately up-regulated in absence of sterols [26]. The dual regulation of LDLR [26] suggests that PCSK9 might be involved in a co-evolutionary network of LDL cholesterol metabolism, i.e., variation at one gene evolving with variation at the other. PCSK9 is only found in vertebrates, suggesting it is the product of recent evolution [27]. However, it is unclear whether natural selection has driven the evolution of PCSK9 in vertebrates, especially in primates.

The ratio of nonsynonymous/synonymous substitution rate (i.e., ω = dN/dS) provides a sensitive measure to detect selective pressure at the protein level [28]. A significantly higher non-synonymous substitution rate than synonymous substitution rate (i.e., dN/dS>1) is evidence for adaptive evolution at the molecular level, whereas dN/dS<1 suggests purifying selection (i.e., selective constraint) [29]. This criterion has been used to identify several cases of positive selection, such as the primate stomach lysozyme (LYZ) [30], [31], and BRCA1 in humans and chimpanzees [32] (for a list of genes under positive selection in the human lineage, see review by Sabeti et al. [33]).

In the present study, we used a phylogeny-based maximum likelihood method to analyze nonsynonymous and synonymous substitution rate of PCSK9 sequences across a range of primates, including Hominoids, Old World monkeys, and New World monkeys. We aimed to address three questions: 1) whether the ratio of nonsynonymous and synonymous evolutionary rate of PCSK9 varied significantly among various primate lineages, 2) whether there is an episodic adaptive evolution of PCSK9 in primates, and 3) which, of any, amino acids of PCSK9 were under positive selection.

Results

Comparative analysis of coding regions of PCSK9

We characterized the coding regions of PCSK9 in human and non-human primates (Table 1). There was considerable evidence for interspecies genomic alterations within PCSK9 (Figure 2). First, in the signal peptide domain, a variable number of CTG codons [encoding Leucine (Leu, L)] were identified (Figure 2). A species-specific nine Leu repeat (L9) was noted only in humans and chimpanzee; whereas in other species, the number of Leu repeats varied from L6 to L8. In the CTG repeat region, interspecies nucleotide differences were synonymous except nonsynonymous changes in the Old World monkeys (CTG→CCA, 46→48) and in spider monkey (CTG→CGG, 67→69). Second, in the C-terminal domain, species-specific loss-of-function mutation was seen in the clade of New World monkeys (via a premature stop codon in tamarin and dusky titi). We speculate that this nonsense mutation leads to a loss-of-function since the adjacent C679X mutation in humans is a loss-of-function mutation.

thumbnail
Figure 2. Protein sequence alignment of PCSK9 in 14 primates.

“.” Indicates identity to the first sequence (i.e., human) in each alignment. “-” indicates an alignment gap, and “X” indicates a stop codon. The coordinates after 84 should be minus one to be consistent with that in Human reference sequence (NP_777596), since an insertion at position 84 was present in the dusky titi. The signal peptide (SP) domain (1–90) shows the evolution of Leucine (Leu) repeats (15–23) in PCSK9, and the C-terminal domain shows the premature stop codon (X) in the tamarin (686), and dusky titi (689).

http://dx.doi.org/10.1371/journal.pone.0001098.g002

Variable dN/dS ratios for the C-terminal domain of PCSK9 among primate lineages

A neighbor-joining (nj) phylogenetic tree of PCSK9 from 14 primate species was reconstructed from the coding sequence alignment, and the maximum likelihood estimate of the tree topology was acquired using the ‘hyphy’ package [34]. We used this gene tree in subsequent analyses to detect whether non-neutral evolution might have operated on PCSK9.

Under a one-ratio model, which assumes the same dN/dS for the entire tree, the cumulative dN/dS for the coding regions of PCSK9 was 0.186 (the log likelihood value l0 = −5109.09). We tested variable dN/dS ratios for PCSK9 among lineages, using the free-ratio model, which assumes a different dN/dS ratio for each branch in the phylogeny (Figure S1). The free-ratio model led to a log likelihood l1 = −5097.59. The free-ratio model was not found to be significantly better than the one-ratio model (the statistic 2Δl = 2(l1l0), P = 0.480, degrees of freedom (df) = 24).

In addition to testing the entire coding regions, it is important to test the structural and functional domains of proteins separately [35]. We evaluated selective pressures in different structural and functional domains by repeating the dN/dS analyses within these domains (the domain structure of PCSK9 is shown in Figure 1). For the C-terminal domain of PCSK9, the free-ratio model (l1 = −1351.35) was found to be significantly better than the one-ratio model (l0 = −1369.71, the cumulative dN/dS = 0.386) (2Δl = 36.72, P = 0.047, df = 24), suggesting variable selective constraint across the phylogeny for the C-terminal domain (Figure 3). We did not observe a significant difference between these two models for each of the other four domains and when the four domains were combined (data not shown).

thumbnail
Figure 3. Ratios of dN/dS estimated for the C-terminal domain of PCSK9 in indicated branches of the primate phylogeny.

Values of dN/dS along each branch were calculated by using the free-ratio model using the CODEML program in ‘PAML’ [72]. Branch lengths were estimated by maximum likelihood under this model. A dN/dS value of >1 suggests that positive selection has acted along that lineage. ‘Inf’ indicates cases where dS = 0. The phylogenetic tree was deduced from the entire coding sequence of PCSK9.

http://dx.doi.org/10.1371/journal.pone.0001098.g003

Non-neutral evolution of the PCSK9 C-terminal domain

Comparison of the rates of nonsynonymous and synonymous DNA changes (i.e., the ratios of dN/dS) between species can be used to assess the types of selective pressures that may have acted on a gene [36]. In the entire PCSK9 sequence, dS exceeded dN in most of the branches in the primate phylogeny (dN/dS<1.0) (Figure S1), indicating that functional constraint (i.e., purifying selection) might have acted on PCSK9 throughout primate evolution. In the branch of bonobo and gorilla, the dN/dS ratio was = 1 (i.e., neutral evolution).

We then compared the values of dN and dS between species in the C-terminal domain of PCSK9 since non-homogeneity in dN/dS ratio was noted among the primate lineages. We found that many branches of the primate phylogeny, including internal branches, showed evidence of evolution under relaxed selective constraint or positive selection (i.e., dN/dS>1.0) (Figure 3). In the Hominoid clade, dN/dS values was infinity (: 7.1/0.0) in the lineage leading to orangutan, and 1.218 (5.1/1.1) to the common ancestors of bonobo and gorrila. The dN/dS in the chimpanzee and human lineages approximated one [0.9890 (4.0/1.1) and 0.5657 (2.0/1.0), respectively], indicating relaxed selective constraint in these two lineages. In addition, we noted dN/dS>1 in lineages leading to colobus and rhesus macaque in the clade of Old World monkeys, as well as spider monkey, squirrel monkey, and the common ancestors of marmoset and tamarin (Figure 3). Thus, the C-terminal domain has been subject to positive selection for at least 33 million years (i.e., the primate divergence time) [37].

Then, by two-ratio likelihood tests using PAML, we tested for the presence of positive selection in the C-terminal domain of PCSK9 in the branch of orangutan and the lineage leading to the common ancestors of bonobo and gorilla in the Hominoid clade. Log likelihood values and dN/dS estimates from each maximum likelihood model were considered, and the likelihood ratio test results are presented in Table 2. The null hypotheses 1–3 were rejected, indicating that the dN/dS ratio in the branch of orangutan is significantly higher than the background ratio of dN/dS (i.e., the null hypothesis of dN/dS ratio homogeneity among lineages was rejected). Although the alternative hypotheses of positive selection (dN/dS>1) in the branch of orangutan (null hypotheses 7 and 8 in Table 2) were not accepted at the level of 0.05, the statistical significance was marginal (P = 0.087 and 0.090, respectively). However, we did not observe the dN/dS ratio in the lineage leading to bonobo and gorilla to be significantly different from the background dN/dS ratio.

thumbnail
Table 2. Log likelihood values, parameter estimates under different models, and likelihood ratio statistics (2Δℓ) for dN/dS hypotheses testing.

http://dx.doi.org/10.1371/journal.pone.0001098.t002

To find out whether the C-terminal domain was under relaxed selective constraint or positive selection, we also plotted dN/dS ratios estimated by Nei-Gojobori method for pairwise comparisons within the primates (Figure 4). In the whole gene sequence and non C-terminal domains region, dN/dS was <1 in all pairwise comparisons, indicating a history of functional selective constraint. However, a higher dN/dS value was noted in the C-terminal domain, including dN/dS>1 in five out of 10 pairwise comparisons within Hominoids. For example, a dN/dS ratio of 1.122 was noted in the human vs. orangutan comparison.

thumbnail
Figure 4. Positive selection or relaxed selective constraint of the C-terminal domain of PCSK9.

dN is plotted versus dS for all pairwise combinations of primate sequences. The pairwise ratios of dN/dS were calculated using the Nei-Gojobori method implemented in the package ‘PAML’ [72]. Pairwise combinations of Hominoids (HOM), Old World monkeys (OWM), and New World monkeys (NWM) are plotted; for example, ‘Human’ represents the points that are making comparisons between human and another primate. We plotted the entire sequence, non C-terminal domain, and C-terminal domain separately. The higher pairwise dN/dS ratio in the C-terminal domain suggests that this domain is evolving in a non-neutral model, which maybe due to positive selection or relaxed selective constraint in some lineages. The entire sequence and non C-terminal domain of PCSK9 showed a net signature of purifying selection.

http://dx.doi.org/10.1371/journal.pone.0001098.g004

Amino acids sites under positive selection

Finally, we identified the particular codon sites that have been subject to positive selection using the site-models [38], [39] and the branch-site models [40]. Table 3 lists the log likelihood values and parameter estimates for the C-terminal domain of PCSK9 under several site models and branch-site models. We used two likelihood ratio tests (LRTs) to test for positive selection. In the site models, the first test compared M1a (neutral) against M2a (selection) [38], [40], [41], in which 2Δl is 0.68 (df = 2, P>0.05), and no amino acid sites were under positive selection. The second test compared M7 against M8, in which no sites were shown under positive selection (2Δl = 1.66, P>0.05). We also used the branch-site model A to detect the codon sites under positive selection by the Bayes Emprical Bayes (BEB) approaches in the lineage of orangutan (i.e., the foreground lineage) [40]. The 2Δl between the null model (neutral, l = −1366.56) and the alternative model (selection, l = −1363.55) is 6.02. The critical values at the 5% and 1% levels for the LRT are 2.71 and 5.41, respectively [42]. Thus, the test for the branch-site model A is significant (df = 2, P<0.01), indicating presence of codon sites under positive selection (544A, 551H, 556G, 661V, and 681S, Pb>95%) in the C-terminal domain of PCSK9.

thumbnail
Table 3. Log likelihood values and parameter estimates under the site models and branch-site models.

http://dx.doi.org/10.1371/journal.pone.0001098.t003

Sliding window analysis

The dN/dS profiles in the sliding window analysis across PCSK9 sequence are shown in Figure 5. As expected, the cumulated dN/dS ratio in primates in the sliding window analysis appear quite stochastic and bears weak correlation to the domain structure, although the dN/dS is slightly higher in the C-terminal domain. However, in the lineages leading to humans and orangutan, we observed that nonsynonymous substitutions were significantly more concentrated within C-terminal domain of PCSK9 (i.e., three dN/dS peaks). The dN/dS peaks were consistent between the lineage leading to humans and to orangutan.

thumbnail
Figure 5. Sliding-window analysis of the cumulative dN/dS across primates (black), the lineage leading to human (green), and orangutan (blue).

The gene average dS across primates is 0.5680, in the lineage leading to human is 0.0030, and orangutan is 0.0204.

http://dx.doi.org/10.1371/journal.pone.0001098.g005

Discussion

The main finding of our study is that there is evidence for functional constraint (i.e., purifying selection) in the coding sequences of PCSK9 through primate evolution. We noted that a functional domain of PCSK9 (i.e., C-terminal domain) was less conserved at the amino acid level than other gene regions, and likelihood ratio tests (LRTs) revealed evidence of positive selection in the lineage leading to orangutan of the Hominoid clade on this domain. Furthermore, we identified the particular codon sites that have been subject to positive selection in this lineage. We discuss the implications of these comparative sequence data for understanding the evolutionary history of primate PCSK9, hypotheses concerning their role in primate phenotypic evolution, and insights into PCSK9-associated human diseases.

Evolutionary history of Leucine (L) repeats in the signal peptide (SP) domain and premature stop codon in the C-terminal domain

Comparative sequence analysis revealed a dynamic evolutionary history of leucine (Leu, L) repeats in the signal peptide domain. The number of Leu repeats varied from L9 to L6 among different clades (Figure 2). An additional in-frame insertion (CTG) leading to a L9→L10 polymorphism in African-Americans and Caucasians [19] is associated with hypocholesterolemia. We speculate that the number of Leu repeat may influence levels of the PCSK9 protein and thereby levels of LDL cholesterol, although this needs confirmation.

In the C-terminal domain of PCSK9, a premature stop codon was seen in the New World monkeys – tamarin and dusky titi (Figure 2) – but not in the Hominoids. As mentioned before, monkeys have significantly lower LDL cholesterol levels than Hominoids [22]. It is unknown whether the loss-of-function mutation in the C-terminal domain is a random phenomenon or a common feature that influences cholesterol metabolism. A premature stop codon mutation in human PCSK9 (C679X) is considered to be under positive selection, and it is speculated that loss of PCSK9 function interferes with the life cycle of the malaria parasite through cholesterol restriction [43], [44]. The “less-is-more” hypothesis of Olson [45] posits that loss of gene function during hominoid evolution may in some cases have conferred a fitness benefit and led to adaptive evolution that may help explain differences among primates [46].

Amino acid substitution patterns

The dN/dS ratio for the coding regions of PCSK9 across the primate species was <1 (cumulative dN/dS = 0.186). There were no lineages with dN/dS>1, and dN/dS ratios did not vary among branches (P = 0.480, Figure S1). This is not unexpected, as averaging dN/dS across all sites is not a powerful test of adaptive evolution [39]. However, the nonsynonymous substitution rate in the C-terminal domain was significantly higher than in other domains. The cumulative dN/dS = 0.386 is higher than that in the entire coding region (dN/dS = 0.186), suggesting that different selection pressures have acted on amino acid changes across different functional regions of this gene.

The hypothesis of dN/dS homogeneity among branches was rejected for the C-terminal domain (P = 0.047, Figure 3), which could reflect either relaxed selective constraint or positive selection for amino acid substitution along one or more lineages. We were particularly interested in two lineages in the Hominoid clade leading to orangutan (dN/dS = infinity), as well as the common ancestor of bonobo and gorilla (dN/dS = 1.213), and tested whether the dN/dS ratio was significantly >1 on these two branches. Likelihood ratio tests (LRTs) from a two-ratio model revealed that positive selection (dN/dS>1) had acted on the orangutan lineage although the statistical evidence was marginal (P = 0.087 and P = 0.090) (Table 2). However, the pattern of dN/dS heterogeneity across lineages is consistent with a relaxed selective constraint. The recently developed branch-site model A is powered to detect the particular amino acid sites that have been subject to positive selection in a given lineage (i.e., a foreground branch) [40], [47], and at least five positively selected amino acids of the C-terminal domain existed in the lineage leading to orangutan (Table 3). No amino acids under positive selection were detected using site models (Table 3). It should be noted that the power of the LRTs is dependent on the number of coding sequences [48]. We sampled 14 primate species in Hominoid, Old World monkey, and New World monkey clades in our phylogenetic analyses (Table 1). A greater number of the species might have permitted more robust inferences of positive selection on the C-terminal domain of PCSK9.

The sliding-window analysis ratio further characterized the non-random nonsynonymous substitution along PCSK9 and dN/dS peaks were obvious in the C-terminal domain (Figure 5). Although the dN/dS ratio in the lineage of humans is <1 (dN/dS = 0.566), three striking peaks of dN/dS (> 4) in human lineage were noted in the C-terminal domain. However, these peaks could be partly explained on the basis that human PCSK9 shows very little synonymous divergence (dS = 0.003).

In the present study, we calculated the dN/dS ratios across the phylogenetic tree using the ‘gene’ tree instead of the ‘species’ tree. We also performed analyses using the ‘species’ tree [49], in which bonobo is most closely related to chimpanzee and gorilla is sister to the human/chimpanzee clade. Although the log likelihood values (l0 for one-ratio model and l1 for free-ratio model) under the ‘species’ tree were different from that under the ‘gene’ tree, we did not find a significant difference in the dN/dS ratio between the ‘species’ tree and ‘gene’ tree for the coding regions and C-terminal domain. Although we did not observe dN/dS ratio >1 in the lineage leading to bonobo or gorilla in the C-terminal domain, we did note dN/dS = infinity in the lineage leading to orangutan. In addition, we used the branch-site A model to test for positive selection in the lineage leading to orangutan based on the species tree. The 2Δl between the null model (neutral, l = −1408.2) and the alternative model (selection, l = −1406.7) is 3.0 (df = 2, P<0.05) (critical value is 2.71 at 5% significance level [42]). We detected three codon sites under positive selection (544A, 551H, and 681S, Pb>95%) in the C-terminal domain of PCSK9 (using BEB analysis). Zhang et al. [47] suggested a critical value of 3.84 (for P<0.05), however, such a threshold may be too conservative for a sequence length of 200 codons [47].

Structural and functional implication of PCSK9

The correct folding of the C-terminal domain is crucial for PCSK9 function but catalytic activity is not required for PCSK9 to bind and degrade LDL-R in cultured human hepatoma cells [50]. The C-terminal domain of a proprotein convertase contains unique sequences regulating their cellular localization and trafficking [51]. For example, PCSK9 exhibits a Cys-His-rich domain that is required for cell surface binding in an LDL-R-dependent fashion [6] and plays a role in the regulation of auto-processing of PCSK9. The structural characteristic of C-terminal domain may determine the colocalization of PCSK9 with LDLR at the cell surface [52] or lead to other novel functional properties. Hence, positive selection operating on the C-terminal domain was most likely directed at creating novel biochemical properties.

Species-specific differences in PCSK9 expression patterns have been noted in brain and liver among humans, chimpanzee, and orangutan [53]. PCSK9 is transiently expressed during embryonic development in telencephalon and cerebellum where LDLR expression is not prominent [6], [54]. Specific knockdown of Pcsk9 mRNA led to embryonic death at 4 days after fertilization in zebrafish [54], and complete knockout of Pcsk9 in mouse led to a ∼50% reduction in circulating levels of LDL cholesterol, but did not result in a lethal phenotype [55]. Over-expression of PCSK9 induces apoptosis in neural development [6], [56], which results in a higher percentage of differentiated neurons and promotes cortical neurogenesis. These results indicate a novel function of PCSK9 in central nervous system development, distinct from that in cholesterogenic organs such as liver [54]. One could hypothesize that relaxed selective constraint or positive selection has operated on the C-terminal domain of PCSK9 due to the key role of PCSK9 in early brain development.

Implications for human diseases

There is increasing interest in identifying gene loci affected by natural selection since they are medically important [57][63]. Loss-of-function or gain-of-function mutations in PCSK9 have been reported to be associated with significant alterations in plasma levels of LDL cholesterol (Figure 1). Both evolutionary conservation indicating negative purifying selection and accelerated evolution driven by positive selection signify functionally significant regions of the genome [64]. To assess the potential severity of human PCSK9 mutations, we assessed the levels of conservation or divergence of non-synonymous mutations listed in Figure 1 by aligning the amino acids among 14 species (Figure 2). We expected that the amino acids known to be important for PCSK9 function (i.e., residues at which disease-causing mutations occur) would be highly conserved. All gain-of-function mutations in PCSK9 leading to hypercholesterolemia in humans are 100% conserved at the amino acid level across all the primates we sampled. In case of loss-of-function mutations leading to hypocholesterolemia, all but two (E57K and Q554E) are 100% conserved across the primates. Mutations leading to both hypercholesterolemia and hypocholesterolemia appear to be less conserved, since four out of seven such mutations are not all conserved, including A53V, I474V, Q554E, and E670G. We noted a striking pattern of I474V variation (SNP rs562556) across the primates. The ancestral state of the 474th amino acid (M or V) in New World monkeys is not clear given the lack of an outgroup. The ‘V’ allele diverged to ‘I’ or ‘V’ in the Hominoid clade, suggesting a dynamic evolutionary history of the 474th amino acid. The human mutation I to V replicates the ancestral state, and the recurrence of this ancestral state has functional consequences [65].

To survey polymorphisms within human populations, we analyzed PCSK9 SNPs using resequenced data from 24 African-Americans and 23 European-Americans (i.e., 47 individuals) in SeattleSNPs database (pga.gs.washington.edu/). A total of 229 polymorphic sites in African-Americans and 125 polymorphic sites in European-Americans were found in the human panel, eight of which resulted in amino acid changes. In addition, an in-frame insertion/deletion (CTG) in the signal-peptide domain was noted in both populations. Six of the eight non-synonymous sites are located in the putative domain and C-terminal domain (some investigators combine these two domains as ‘C-terminal’ domain), corresponding to the regions that have been predicted to be under positive selection. None of the non-synonymous sites was found in the catalytic domain. We used SIFT [66] and PolyPhen [67] to predict the effect of the amino acid changes (Table S2). In case of amino acid 474, the nonsynonymous substitution was predicted to be damaging (i.e., cause functional alteration), but the derived allele frequency of 0.79 in African-Americans and 0.87 in European-Americans suggests that positive selection acted to increase the frequency of this polymorphism. In humans, a signature of recent positive selection was noted on this common variation using long-range haplotype (LRH) test; that is, positive selection had acted on the derived allele ‘I’ in African-Americans and the ancestral allele ‘V’ in European-Americans (Ding and Kullo, manuscript in revision). In addition, a signature of positive selection on the derived allele of E670G (rs505151), which resides in the C-terminal domain, was also noted in African-Americans. We speculate that non-conserved mutations across the primates might be the substrate for non-neutral evolution and responsible for the phenotypic variation in the general population.

In conclusion, phylogenetic analysis of the cholesterol metabolism gene PCSK9 across a range of primates reveals lineage-specific patterns of variation. Although the gain-of-function mutations at PCSK9 reflect strong functional constraint and a history of purifying selection, a signature of relaxed selective constraint or positive selection was noted in the C-terminal domain of PCSK9. It is possible that different modes of selection have operated on different functional domains of PCSK9.

Materials and Methods

Primate Genomic DNA Sources

The comparative sequences of the PCSK9 coding regions were obtained in 14 species from three sources. First, the human (accession no.: NM_174936) and chimpanzee (XM_427085) mRNA sequences of PCSK9 were downloaded from NCBI (www.ncbi.nlm.nih.gov). Next, we acquired the BAC (bacterial artificial chromosome) clone sequence including PCSK9 from Programs for Genomic Application (PGA) at Berkeley (pga.lbl.gov/seq), including colobus (AC188217), dusky titi (AC188268), squirrel monkey (AC188233), and marmoset (AC188221). Coding regions of PCSK9 for these species were extracted by aligning the human mRNA sequence to the BAC sequence using the ‘sim4’ program [68]. Finally, DNA samples for a primate panel, including rhesus macaque, pigtailed macaque, bonobo, gorilla, chimpanzee, orangutan, tamarin, spider monkey, woolly monkey, and lemur, were obtained from Coriell Cell Repositories (Camden, NJ). The species name and scientific name for each species are listed in Table 1.

Sequencing of PCSK9 exons from Primate Genomic DNA

In the primate panel, PCSK9 was amplified and sequenced exon by exon from genomic DNA with high fidelity polymerase chain reaction (PCR). Primers and PCR conditions are listed in Table S1. PCR products were sequenced directly in both forward and reverse directions. Exon reads were assembled together to create virtual transcript for each primate using the Sequencher® program (version 4.5, www.genecodes.com) and visually checked for accuracy. The lemur PCSK9 sequence could not be obtained due to difficulty in PCR amplification. Sequences of coding regions for eight species in this primate panel were obtained. A total of 2072 bp of PCSK9 coding sequence (the length is based on the human sequence and excludes the stop codon) in 14 species was compiled. All sequences have been submitted to the GenBank database under the accession nos. EF692496–EF692509 (Table 1).

Detecting lineage-specific episodes of positive selection

Sequences were aligned using ClustalW [69], followed by manual inspection and analysis. We used the ‘HYPHY’ package to estimate the topology of phylogenetic tree using the maximum likelihood method [34]. Since the gene tree was different from the species tree, analyses were done based on gene tree as well as the species tree.

We used the maximum likelihood method based on codon-substitution model by Yang [28], [31], [70] to test whether there was a significant difference in dN/dS ratio (i.e., ω) among lineages and whether dN/dS was significantly >1 (i.e., positive selection) in a given lineage. The ‘one-ratio’ model assumes the same ratio for all branches in the phylogeny. The most general model – ‘free-ratio’ model – assumes an independent dN/dS ratio for each branch in the phylogeny. If there is a phylogenetic tree of many species, this model involves as many dN/dS parameters as the number of branches in the tree. The models used in the phylogenetic analysis can be compared using the likelihood-ratio test to examine interesting hypotheses [31]. The null hypothesis is the ‘one-ratio’ model, and can be used to test whether there is a differential dN/dS ratio among lineages. Positive selection or relaxed selective constraint in some lineages could contribute to the heterogeneity in the dN/dS ratio.

Detecting amino acid sites under positive selection

The above methods for lineage-specific selection assume that all amino acid sites have the same dN/dS ratio, i.e., averages the dN/dS ratio across all sites. Since many amino sites might be under strong purifying selection due to functional constraint (dN/dS≈zero) and positive selection often operates episodically on a few amino acid sites [47], it seems likely that this is a more conservative test and amino acid sites under positive selection cannot be detected.

Several methods have been developed to address this problem, such as the site models which allow dN/dS to vary among codons [38], [71]. In the present study, we also used an improved branch-site likelihood method to detect positive selection at the amino acid sites [28], [40], [47]. This branch-site model [28], [40], [47] assumed that the branches on the phylogeny are divided a priori into foreground (i.e, may have experienced positive selection) and background lineages. We used the likelihood-ratio test 2 (i.e., the branch-site test of positive selection) constructed from this branch-site model [47]. The null hypothesis of this LRT is the branch-site model A list above but with ω2 fixed = 1, which can be used to directly test for positive selection on the foreground lineages [47]. The Bayes empirical Bayes (BEB) approach was used to calculate the posterior probabilities that a codon belongs to the site class of positive selection on the foreground lineages [40]. The test should be compared with the 50∶50 mixture of point mass 0 and (with critical values to be 2.71 and 5.41, at the 5% and 1% significance levels, respectively) [42]. Zhang et al [47] also suggested the use of distribution for assessing the significance of the test (3.84 and 5.99 at the 5% and 1% significance levels, respectively). This LRT test seemed conservative overall, but exhibited better power in detecting positive selection than the branch-based test [47].

We used the ‘CODEML’ program in PAML version 3.15 [72] to calculate the dN/dS ratio and perform the maximum likelihood phylogenetic analysis. To calculate the dN/dS ratio at lineages (defined as all branches in the phylogeny, both terminal species nodes and internodes), sequences associated with species-specific premature stop codons were removed.

Sliding-window analysis of dN/dS

Sliding-window analysis of dN/dS was performed with a window size of 90 bp (30 codons) and a sliding increment of 15 bp (5 codons). We used the approach by Choi and Lahn [73] to calculate the dN/dS of each window as the ratio between window-specific dN and gene-average dS, since noise in window-specific dS can sometimes hamper the analysis. In addition, the use of gene-average instead of window-specific dS should not introduce any systematic bias [73].

Supporting Information

Figure S1.

Phylogeny of coding regions of PCSK9. PCSK9 was resequenced from a panel of primates including Hominoids, Old World monkeys, and New World monkeys. Branch lengths were estimated by maximum likelihood under the free-ratio model, which assumes an independent dN/dS ratio for each branch.

doi:10.1371/journal.pone.0001098.s001

(0.01 MB EPS)

Table S1.

Polymerase chain reaction (PCR) primers and conditions for PCSK9 exon analyses

doi:10.1371/journal.pone.0001098.s002

(0.10 MB DOC)

Table S2.

SIFT and Polyphen prediction of amino acid polymorphisms

doi:10.1371/journal.pone.0001098.s003

(0.04 MB DOC)

Acknowledgments

We acknowledge the technical support of Mayo Research Computing Facility and the Supercomputing Institute of University of Minnesota, Minneapolis.

Author Contributions

Conceived and designed the experiments: KD IK. Performed the experiments: SM. Analyzed the data: KD IK. Wrote the paper: KD IK.

References

  1. 1. Espenshade PJ, Cheng D, Goldstein JL, Brown MS (1999) Autocatalytic processing of site-1 protease removes propeptide and permits cleavage of sterol regulatory element-binding proteins. J Biol Chem 274: 22795–22804.
  2. 2. Brown MS, Goldstein JL (1999) A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci U S A 96: 11041–11048.
  3. 3. Elagoz A, Benjannet S, Mammarbassi A, Wickham L, Seidah NG (2002) Biosynthesis and cellular trafficking of the convertase SKI-1/S1P: ectodomain shedding requires SKI-1 activity. J Biol Chem 277: 11265–11275.
  4. 4. Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, et al. (2004) NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 279: 48865–48875.
  5. 5. Naureckiene S, Ma L, Sreekumar K, Purandare U, Lo CF, et al. (2003) Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch Biochem Biophys 420: 55–67.
  6. 6. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, et al. (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 100: 928–933.
  7. 7. Lalanne F, Lambert G, Amar MJ, Chetiveaux M, Zair Y, et al. (2005) Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. J Lipid Res 46: 1312–1319.
  8. 8. Maxwell KN, Breslow JL (2004) Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A 101: 7100–7105.
  9. 9. Park SW, Moon YA, Horton JD (2004) Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem 279: 50630–50638.
  10. 10. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, et al. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34: 154–156.
  11. 11. Leren TP (2004) Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet 65: 419–422.
  12. 12. Timms KM, Wagner S, Samuels ME, Forbey K, Goldfine H, et al. (2004) A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 114: 349–353.
  13. 13. Sun XM, Eden ER, Tosi I, Neuwirth CK, Wile D, et al. (2005) Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia. Hum Mol Genet 14: 1161–1169.
  14. 14. Naoumova RP, Tosi I, Patel D, Neuwirth C, Horswell SD, et al. (2005) Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol 25: 2654–2660.
  15. 15. Shioji K, Mannami T, Kokubo Y, Inamoto N, Takagi S, et al. (2004) Genetic variants in PCSK9 affect the cholesterol level in Japanese. J Hum Genet 49: 109–114.
  16. 16. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, et al. (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37: 161–165.
  17. 17. Kotowski IK, Pertsemlidis A, Luke A, Cooper RS, Vega GL, et al. (2006) A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 78: 410–422.
  18. 18. Berge KE, Ose L, Leren TP (2006) Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol 26: 1094–1100.
  19. 19. Yue P, Averna M, Lin X, Schonfeld G (2006) The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population. Hum Mutat 27: 460–466.
  20. 20. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354: 1264–1272.
  21. 21. Fleagle JG, McGraw WS (1999) Skeletal and dental morphology supports diphyletic origin of baboons and mandrills. Proc Natl Acad Sci U S A 96: 1157–1161.
  22. 22. Crissey S, Barr J, Slifka K, Bowen P, Stacewicz-Sapuntzakis M, et al. (1999) Serum concentrations of lipids, vitamins A and E, vitamin D metabolites, and carotenoids in nine primate species at four zoos. Zoo biology 18: 551–564.
  23. 23. Caceres M, Lachuer J, Zapala MA, Redmond JC, Kudo L, et al. (2003) Elevated gene expression levels distinguish human from non-human primate brains. Proc Natl Acad Sci U S A 100: 13030–13035.
  24. 24. Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109: 1125–1131.
  25. 25. Tall AR (2006) Protease variants, LDL, and coronary heart disease. N Engl J Med 354: 1310–1312.
  26. 26. Attie AD, Seidah NG (2005) Dual regulation of the LDL receptor–some clarity and new questions. Cell Metab 1: 290–292.
  27. 27. Seidah NG, Khatib AM, Prat A (2006) The proprotein convertases and their implication in sterol and/or lipid metabolism. Biol Chem 387: 871–877.
  28. 28. Yang Z, Nielsen R (2002) Codon-substitution models for detecting molecular adaptation at individual sites along specific lineages. Mol Biol Evol 19: 908–917.
  29. 29. Nei M, Kumar S (2000) Molecular evolution and phylogenetics. Oxford: Oxford University Press.
  30. 30. Messier W, Stewart CB (1997) Episodic adaptive evolution of primate lysozymes. Nature 385: 151–154.
  31. 31. Yang Z (1998) Likelihood ratio tests for detecting positive selection and application to primate lysozyme evolution. Mol Biol Evol 15: 568–573.
  32. 32. Huttley GA, Easteal S, Southey MC, Tesoriero A, Giles GG, et al. (2000) Adaptive evolution of the tumour suppressor BRCA1 in humans and chimpanzees. Australian Breast Cancer Family Study. Nat Genet 25: 410–413.
  33. 33. Sabeti PC, Schaffner SF, Fry B, Lohmueller J, Varilly P, et al. (2006) Positive natural selection in the human lineage. Science 312: 1614–1620.
  34. 34. Pond SL, Frost SD, Muse SV (2005) HyPhy: hypothesis testing using phylogenies. Bioinformatics 21: 676–679.
  35. 35. Lynn DJ, Freeman AR, Murray C, Bradley DG (2005) A genomics approach to the detection of positive selection in cattle: adaptive evolution of the T-cell and natural killer cell-surface protein CD2. Genetics 170: 1189–1196.
  36. 36. Hurst LD (2002) The Ka/Ks ratio: diagnosing the form of sequence evolution. Trends Genet 18: 486.
  37. 37. Goodman M, Porter CA, Czelusniak J, Page SL, Schneider H, et al. (1998) Toward a phylogenetic classification of Primates based on DNA evidence complemented by fossil evidence. Mol Phylogenet Evol 9: 585–598.
  38. 38. Nielsen R, Yang Z (1998) Likelihood models for detecting positively selected amino acid sites and applications to the HIV-1 envelope gene. Genetics 148: 929–936.
  39. 39. Yang Z, Nielsen R, Goldman N, Pedersen AM (2000) Codon-substitution models for heterogeneous selection pressure at amino acid sites. Genetics 155: 431–449.
  40. 40. Yang Z, Wong WS, Nielsen R (2005) Bayes empirical bayes inference of amino acid sites under positive selection. Mol Biol Evol 22: 1107–1118.
  41. 41. Wong WS, Yang Z, Goldman N, Nielsen R (2004) Accuracy and power of statistical methods for detecting adaptive evolution in protein coding sequences and for identifying positively selected sites. Genetics 168: 1041–1051.
  42. 42. Self S, Liang K (1987) Asymptotic properties of maximum likelihood estimators and likelihood ratio tests under non-standard conditions. J Am Stat Assoc 82: 605–610.
  43. 43. Horton JD, Cohen JC, Hobbs HH (2007) Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 32: 71–77.
  44. 44. Mbikay M, Mayne J, Seidah NG, Chretien M (2007) Of PCSK9, cholesterol homeostasis and parasitic infections: Possible survival benefits of loss-of-function PCSK9 genetic polymorphisms. Med Hypotheses.
  45. 45. Olson MV (1999) When less is more: gene loss as an engine of evolutionary change. Am J Hum Genet 64: 18–23.
  46. 46. Perry GH, Tito RY, Verrelli BC (2007) The evolutionary history of human and chimpanzee Y-chromosome gene loss. Mol Biol Evol 24: 853–859.
  47. 47. Zhang J, Nielsen R, Yang Z (2005) Evaluation of an improved branch-site likelihood method for detecting positive selection at the molecular level. Mol Biol Evol 22: 2472–2479.
  48. 48. Anisimova M, Bielawski JP, Yang Z (2001) Accuracy and power of the likelihood ratio test in detecting adaptive molecular evolution. Mol Biol Evol 18: 1585–1592.
  49. 49. Purvis A (1995) A composite estimate of primate phylogeny. Philos Trans R Soc Lond B Biol Sci 348: 405–421.
  50. 50. McNutt MC, Lagace TA, Horton JD (2007) Catalytic activity is not required for secreted PCSK9 to reduce LDL receptors in HepG2 cells. J Biol Chem 282: 20799–20803.
  51. 51. Seidah NG, Prat A (2007) The proprotein convertases are potential targets in the treatment of dyslipidemia. J Mol Med 85: 685–696.
  52. 52. Nassoury N, Blasiole DA, Tebon Oler A, Benjannet S, Hamelin J, et al. (2007) The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 8: 718–732.
  53. 53. Enard W, Khaitovich P, Klose J, Zollner S, Heissig F, et al. (2002) Intra- and interspecific variation in primate gene expression patterns. Science 296: 340–343.
  54. 54. Poirier S, Prat A, Marcinkiewicz E, Paquin J, Chitramuthu BP, et al. (2006) Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system. J Neurochem 98: 838–850.
  55. 55. Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, et al. (2005) Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A 102: 5374–5379.
  56. 56. Bingham B, Shen R, Kotnis S, Lo CF, Ozenberger BA, et al. (2006) Proapoptotic effects of NARC 1 ( = PCSK9), the gene encoding a novel serine proteinase. Cytometry A 69: 1123–1131.
  57. 57. Hahn MW, Rockman MV, Soranzo N, Goldstein DB, Wray GA (2004) Population genetic and phylogenetic evidence for positive selection on regulatory mutations at the factor VII locus in humans. Genetics 167: 867–877.
  58. 58. Nakajima T, Wooding S, Sakagami T, Emi M, Tokunaga K, et al. (2004) Natural selection and population history in the human angiotensinogen gene (AGT): 736 complete AGT sequences in chromosomes from around the world. Am J Hum Genet 74: 898–916.
  59. 59. Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, et al. (2004) CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 75: 1059–1069.
  60. 60. Rockman MV, Hahn MW, Soranzo N, Loisel DA, Goldstein DB, et al. (2004) Positive selection on MMP3 regulation has shaped heart disease risk. Curr Biol 14: 1531–1539.
  61. 61. Young JH, Chang YP, Kim JD, Chretien JP, Klag MJ, et al. (2005) Differential susceptibility to hypertension is due to selection during the out-of-Africa expansion. PLoS Genet 1: e82.
  62. 62. Ding K, Kullo IJ (2006) Molecular evolution of 5′ flanking regions of 87 candidate genes for atherosclerotic cardiovascular disease. Genet Epidemiol 30: 557–569.
  63. 63. Kullo IJ, Ding K (2007) Patterns of population differentiation of candidate genes for cardiovascular disease. BMC genetics 8: 48.
  64. 64. Thomas JW, Touchman JW, Blakesley RW, Bouffard GG, Beckstrom-Sternberg SM, et al. (2003) Comparative analyses of multi-species sequences from targeted genomic regions. Nature 424: 788–793.
  65. 65. Schaner P, Richards N, Wadhwa A, Aksentijevich I, Kastner D, et al. (2001) Episodic evolution of pyrin in primates: human mutations recapitulate ancestral amino acid states. Nat Genet 27: 318–321.
  66. 66. Ng PC, Henikoff S (2003) SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 31: 3812–3814.
  67. 67. Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30: 3894–3900.
  68. 68. Florea L, Hartzell G, Zhang Z, Rubin GM, Miller W (1998) A computer program for aligning a cDNA sequence with a genomic DNA sequence. Genome Res 8: 967–974.
  69. 69. Thompson JD, Higgins DG, Gibson TJ (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673–4680.
  70. 70. Yang Z, Goldman N, Friday A (1994) Comparison of models for nucleotide substitution used in maximum-likelihood phylogenetic estimation. Mol Biol Evol 11: 316–324.
  71. 71. Yang Z, Bielawski JP (2000) Statistical methods for detecting molecular adaptation. Trends in Ecology and Evolution 15: 496–503.
  72. 72. Yang Z (1997) PAML: a program package for phylogenetic analysis by maximum likelihood. Comput Appl Biosci 13: 555–556.
  73. 73. Choi SS, Lahn BT (2003) Adaptive evolution of MRG, a neuron-specific gene family implicated in nociception. Genome Res 13: 2252–2259.